Company profile for Dompe Farmaceutici

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Dompé is a privately owned biopharmaceutical company with 130 years of experience. Headquartered in Milan, we operate in Boston, San Francisco, and Shanghai. Dompé is committed to medical and scientific advancement, through our own research and open innovation ecosystem. We have developed the first application of rhNGF (recombinant human Nerve Growth Factor) as a commercial therapy. Dompé's rhNGF is the first and only phar...
Dompé is a privately owned biopharmaceutical company with 130 years of experience. Headquartered in Milan, we operate in Boston, San Francisco, and Shanghai. Dompé is committed to medical and scientific advancement, through our own research and open innovation ecosystem. We have developed the first application of rhNGF (recombinant human Nerve Growth Factor) as a commercial therapy. Dompé's rhNGF is the first and only pharmacologic treatment specifically indicated for Neurotrophic Keratitis, approved by the FDA and EMA.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Italy
Address
Address
Via Santa Lucia, 6 20122 Milano
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761094

FDA
20 Oct 2023

https://www.indianpharmapost.com/news/eni-and-dompe-farmaceutici-join-forces-for-health-research-14773

ECONOMIC TIMES
11 Oct 2023

https://www.businesswire.com/news/home/20231010466159/en

BUSINESSWIRE
10 Oct 2023

https://www.prnewswire.com/news-releases/dompe-new-published-data-point-to-spike-protein-interactions-with-estrogen-receptors-as-a-cause-for-coagulopathy-in-covid-19-patients-signaling-sex-effects-and-a-path-to-improved-vaccines-301690590.html

PRNEWSWIRE
30 Nov 2022

https://www.prnewswire.com/news-releases/two-clinical-studies-to-treat-mild-to-moderate-covid-19-at-home-reveal-value-of-exscalate-dompes-ai-platform-for-drug-design-301592560.html

PRNEWSWIRE
26 Jul 2022

https://www.prnewswire.com/news-releases/dompe-announces-results-of-phase-2-study-evaluating-the-efficacy-and-safety-of-reparixin-in-patients-with-severe-covid-19-pneumonia-301566589.html

PRNEWSWIRE
13 Jun 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty